Trend

QS Research · Michael Burry's Scion Capital analyst template · 2006

IQVIA HOLDINGS INC. (IQV)

As of 2026-11-17 · 12/15 boxes filled from SEC filings and market data

Report price $264.73 (close 2026-11-16); latest close $245.82 (2026-11-20), -7.1% since the report; figures re-marked at the latest close

Conclusion: WATCH

Conviction medium · base case +25% · downside -21% · upside +29%

The market is pricing IQVIA at 31.3x TTM net income, essentially its own 31.1x five-year median and below the 36.2x peer median P/E. The call is WATCH because the peer multiple is not clearly too low: FY2025 showed no operating leverage, many R&D clients can terminate on short notice, and net debt is $13.64B. The downside is -26.5% to $194.58 on -10.0% earnings at a compressed P/E of 25.65x (today 31.3x). The base is +15.7% to $306.17 with P/E at 36.2x, the peer median P/E (5 peers in the comps table: ICLR 62.5x, MEDP 35x, TMO 36.2x, LH 30.1x, VEEV 47.8x). The upside is +20.0% to $317.68 on +20% earnings at today's P/E of 31.3x. GAAP EBITDA (TTM) is the EBITDA basis.

Key numbers

  • Share price: $245.82
  • Market cap: $40.51B
  • Latest financial period: TTM to Sep 30, 2026
  • Revenue (TTM): $17.31B
  • EV / EBITDA (TTM): 15.8x
  • P/E (TTM): 29.1x
  • FCF yield: 5.2%
  • Price / book: 6.08x
  • Earnings-quality flags (TTM): none flagged
  • EV / FCF (TTM): 26.0x
  • Revenue growth (latest fiscal year): +5.9%
  • ROIC (TTM): 9.0%
  • WACC: 7.2%
  • Economic profit spread: +1.8 pts

The 15 boxes

  1. ✓ 1. Long-form business notes

    IQVIA sells clinical research services, healthcare data and analytics, and commercial outsourcing to life sciences companies: three reportable segments (Technology & Analytics Solutions, Research & Development Solutions, Contract Sales & Medical Solutions) until the January 1, 2026 reorganization into two, Commercial Solutions and Research & Development Solutions. All figures in the data window are post the acquisition program: revenue ran from $11.36B in FY2020 to $16.31B in FY2025 and $17.31B on a TTM basis to September 30, 2026, with GAAP operating income of $731.0M in FY2020 rising to $2.18B in FY2025 and $2.22B TTM. The GAAP operating line is struck after heavy intangible amortization ($984.0M in FY2025; $1.14B combined D&A), so the EBITDA basis used here is GAAP operating income plus that combined D&A tag. Between the FY2020 and FY2025 annual reports headcount went from about 70,000 to about 93,000, proprietary data from about 45 to about 68 petabytes, and the company's own cited market from greater than $260B to about $335B.

  2. ✓ 2. Competitive advantage

    The record shows scale economics: revenue rose from $11.36B (FY2020) to $16.31B (FY2025) and $17.31B (TTM to 2026-09-30) while GAAP operating income went from $731.0M to $2.18B and $2.22B, and operating cash flow reached $2.74B TTM on capex of only $657M. But FY2025 shows no operating leverage (revenue +$910M, GAAP operating income down $20M), and the 10-K's own risk factors say most R&D Solutions clients can walk on 30-90 days' notice and that the data the Commercial Solutions business sells is licensed from third parties. The advantage claimed is breadth and geographic reach vs a long list of rivals, not a measured share or pricing power; no adjusted EBITDA, segment margin or retention data is in these sources, so this section uses GAAP operating income and operating cash flow only.

  3. ✓ 3. 10-Q takeaways

    Q3 2026 revenue was $4,428 million, up 8.0% reported and 8.6% constant currency, with Adjusted EBITDA of $1,032 million (up 8.7%) and Adjusted Diluted EPS of $3.34 (up 11.3%); nine-month revenue was $12,947 million, up 8.4%. Cost of revenues fell to 66.2% of revenue from 66.5% while SG&A rose to 12.9% from 12.5%, and GAAP Net Income of $350 million ($2.10 per diluted share) trails the $557 million adjusted figure partly because of $36 million of restructuring in the quarter. R&DS backlog was reset to $32.6 billion after a $2.1 billion reduction for inactive trials, with $9.4 billion expected to convert in the next twelve months, and full-year 2026 guidance was raised to $17,350-$17,500 million revenue, $4,025-$4,055 million Adjusted EBITDA and $12.90-$13.00 Adjusted Diluted EPS. Cash was $2,249 million against $16,172 million of total indebtedness at September 30, 2026, and risk factors were unchanged from the 2025 Form 10-K.

  4. ✓ 4. Corporate governance

    Filled; members read this box.

  5. ✓ 5. Overview of the prior 3 years of 8-K filings

    Filled; members read this box.

  6. ✓ 6. Other significant filings

    Filled; members read this box.

  7. ✓ 7. Chronology of significant news and events

    Filled; members read this box.

  8. ✓ 8. Comparables valuation interpretation

    Filled; members read this box.

  9. ✓ 9. Insider trading interpretation

    Filled; members read this box.

  10. ○ 10. Earnings-call notes
  11. ○ 11. Impression of the shareholder letter
  12. ○ 12. Scuttlebutt overview
  13. ✓ 13. Valuation and risk/reward summary

    Filled; members read this box.

  14. ✓ 14. Current price suppression and potential catalysts

    Filled; members read this box.

  15. ✓ 15. Conclusions

    The call above.

Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.

Put these signals to work

The Scion template's preview is free. Paid members read every box of every report. FST, the QuantSignals trading agent, uses QS Research as its brain.

Join freeMeet FSTSee plans